



SEQUENCE LISTING

<110> Quirk, Stephen

Tyrrell, David

<120> Design and Use of Advanced Zinc Chelating Peptides to Regulate Matrix Metalloproteinases

<130> 44039-227522 11301-0200

Sur B1
<140> US 09/753,139

<141> 2000-12-29

<160> 10

<170> PatentIn version 3.0

a'
<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<220>

<221> VARIANT

<222> (2)..(2)

<223> X = Ser or Thr

<220>
<221> VARIANT
<222> (4)..(4)
<223> X = Ser, Ala or Val

<400> 1
Cys Xaa Cys Xaa Pro His Pro
1 5
<210> 2
<211> 12
<212> PRT
<213> Artificial Sequence

β
β
β
<220>
<223> Synthetic Peptide
<220>
<221> VARIANT
<222> (1)..(1)
<223> X = Ile or Val

α
α
α
<220>
<221> VARIANT
<222> (2)..(2)
<223> X = Glu, Gln or Arg

<220>
<221> VARIANT
<222> (3)..(3)
<223> X = Phe or Tyr

<220>
<221> VARIANT
<222> (4) .. (4)
<223> X = Ile or Val

<220>
<221> VARIANT
<222> (5) .. (5)
<223> X = Tyr or His

Sub B cont
<220>
<221> VARIANT
<222> (7) .. (7)
<223> X = Ala, Pro or Glu

A Cont
<220>
<221> VARIANT
<222> (8) .. (8)
<223> X = Pro, Phe or Ala

<220>
<221> VARIANT
<222> (9) .. (9)
<223> X = Ser, Asp or Met

<220>
<221> VARIANT
<222> (10) .. (10)

<223> X = Ala or Ser

<220>

<221> VARIANT

<222> (11) .. (11)

<223> X = Val or Leu

<220>

<221> VARIANT

<222> (12) .. (12)

<223> X = Cys or Gly

*Sub B
cont*

<400> 2
Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 3

<211> 9

<212> PRT

*a
Cont*

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<220>

<221> VARIANT

<222> (1) .. (1)

<223> X = Met, Val or Leu

<220>

<221> VARIANT

<222> (2) .. (2)
<223> X = His, Phe or Tyr

<220>
<221> VARIANT
<222> (3) .. (3)
<223> X = Ile or Thr

<220>
<221> VARIANT
<222> (4) .. (4)
<223> X = Thr, His or Gly

*Side B
cont*
<220>
<221> VARIANT
<222> (5) .. (5)
<223> X = Leu or Thr

<220>
<221> VARIANT
<222> (7) .. (7)
<223> X = Asp, Asn or Ser

<220>
<221> VARIANT
<222> (8) .. (8)
<223> X = Phe or Tyr

<220>

<221> VARIANT
<222> (9) .. (9)
<223> X = Ile or Val

<400> 3
Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5

<210> 4
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide
Cys Ser Ala Val Pro Val His
1 5
<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Peptide
Asp Ser Ala Val Pro Val His
1 5
<210> 6
<211> 9
<212> PRT

*Sub
B1
Unt
A
Cont*

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 6

Ile Tyr Thr Ala Cys Met Ser Ala Val

1 5

<210> 7

<211> 7

<212> PRT

<213> Artificial Sequence

Sub P

<220>

<223> Synthetic Peptide

<400> 7

Val His Thr His Leu Cys Asp

1 5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 8

Cys Thr Cys Val Pro

1 5

<210> 9

<211> 4

<212> PRT

a
Cont

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 9

Cys Asp Ile Cys
1

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

a'

<220>

<223> Synthetic Peptide

<400> 10

His Thr Ile Thr His
1 5